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A commentary on
Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene
expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm
shift
by Hertz, L., Rothman, D. L., Li, B., and Peng, L. (2015). Front. Behav. Neurosci. 9:25. doi:
10.3389/fnbeh.2015.00025
Working on the serotonin (5-hydroxytryptamine, 5-HT) 5-HT2B receptor since several years, we
have read with high interest the review by Hertz et al. (2015). Previous studies from our group
demonstrated that a direct injection in mouse raphe nucleus of the 5-HT2B agonist BW723C86
has the ability to increase extracellular levels of serotonin, which can be blocked by the selective
5-HT2B receptor antagonist RS127445 (Doly et al., 2008, 2009). We also reported that an acute
injection of paroxetine 2mg/kg in mice knocked out for the 5-HT2B receptor gene or in wild type
mice injected with RS127445 (0.5mg/kg) triggers a strong reduction in extracellular accumulation
of 5-HT in hippocampus (Diaz et al., 2012). Following these observations, we showed that acute
and chronic BW723C86 injection (3mg/kg) can mimic the fluoxetine (3mg/kg) and paroxetine
(1mg/kg) behavioral and biochemical antidepressant effects in mice (Diaz and Maroteaux, 2011;
Diaz et al., 2012).
Hertz and coworkers used some of our published data on mice to support that fluoxetine
and other SSRIs are acting as direct 5-HT2B receptor agonists independently of the serotonin
transporter (SERT), based on their work on astrocytes. These authors forgot other important
informations provided in Diaz’s paper (Diaz et al., 2012), i.e., the absence of antidepressant effects
of either fluoxetine or BW723C86 in mice lacking either the serotonin transporter (knockout for
SERT) or differentiated serotonin neurons (knockout for Pet1). These data (i) rule out that the
antidepressant effects of the 5-HT2B agonist BW723C86 or of fluoxetine could be independent
of SERT; (ii) they indicate that serotonin neurons expressing SERT (and 5-HT2B receptors) are
necessary for the 5-HT2B receptor effects independently of other cell types; (iii) they rule out the
possibility that SSRIs mediate antidepressant effects only by stimulating directly putative astrocytic
5-HT2B receptors, which should be intact in these two mutant mice (SERT KO and Pet1 KO). A
previous work (Launay et al., 2006) demonstrated a 5-HT2B receptor-mediated control of SERT
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TABLE 1 | Affinity constants (pKi) for different binding compounds to
Human 5-HT2C and 5-HT2B receptors.
Compounds 5-HT2B Human 5-HT2C Human
pkI Ki (nM) pKi Ki (nM)
Fluoxetineb <5 >10,000 6.95 112
Norfluoxetineb <5 >10,000 7.04 91
Paroxetineb <5 >10,000 <5 >10,000
Fluoxetinek <5 >10,000 6.40± 0.03 400
BW723C86k 7.33± 0.03 47 7.11± 0.21 78
Pharmacological determinations were performed on transfected cells expressing the
relevant receptor by heterologous competition. Values are from Bonhaus et al. (1997)
(b ) and Knight et al. (2004) (k ).
activity in primary neurons from raphe nuclei, in which
the BW723C86/5-HT2B receptor coupling promotes
phosphorylations of SERT that can easily explain our findings in
mice by a direct regulation of SERT by 5-HT2B receptors in a cell
autonomous manner.
Furthermore, Hertz and coworkers state “The ability of all
five currently used SSRIs to stimulate the 5-HT2B receptor
equipotentially in cultured astrocytes has been known for
several years.” This information originates from one of their
previous observation on astrocyte cultures that “Onemicromolar
of paroxetine, fluvoxamine or sertraline increased cPLA2a
expression during chronic treatment; citalopram had a similar
effect at 0.1–0.5µM” (Zhang et al., 2010). Hertz and coworkers
validated these data in one of their former review (Hertz
et al., 2012), which reproduced their own earlier data (Kong
et al., 2002), showing an half maximum effect (competition of
mesulergine by fluoxetine on astrocytes) of 1µM. However, in
this review, they say that this initial calculation was “incorrect”
and indicated that the Ki value of fluoxetine was in fact 70 nM
on putative 5-HT2B astrocytic receptors (Hertz et al., 2012).
These values, which are not supported by other published
experimental evidence by these authors, are divergent from
all published pharmacological values obtained with identified
receptors: Bonhaus et al. (1997) and Knight et al. (2004) found
Ki values for cloned human 5-HT2B receptors over 10µM for
fluoxetine, norfluoxetine and paroxetine (Table 1).
To sum up, it is clear from our experiments in mice that
acute or chronic fluoxetine (and paroxetine) cannot act by
a direct 5-HT2B receptor stimulation independently of SERT
and serotonergic neurons. Furthermore, our pharmacological
determination in mice is in accordance with affinity of SSRIs for
human 5-HT2B receptors with Ki values over 5µM (Diaz et al.,
2012) and with no agonist activity (unpublished), while SSRI
Ki values for SERT are in nanomolar range. Many SSRIs have
published Ki values around 1µM for muscarinic acetylcholine
and histamine receptors or other monoamine transporters. The
contribution of these other receptors/transporters in astrocytes
could explain the findings of Hertz and coworkers independently
of putative direct agonist effects at 5-HT2B receptors. Finally, the
published evidence for 5-HT2B receptor expression in microglia
(Krabbe et al., 2011; Kolodziejczak et al., 2015) add another
level of complexity, as the concept of the tripartite synapse has
recently been expanded to the monoaminergic systems to explain
antidepressant drug responses (Quesseveur et al., 2013). A full set
of research is still needed to understand the putative role for 5-
HT in glial cells including astrocytes and/or microglia in respect
to the relationship between SSRIs, serotonergic neurons and 5-
HT2B receptors. The needs for further research is warranted
to determine how this receptor subtype contribute to SSRI
antidepressant effects.
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